Natasha Robin Berman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natasha Robin Berman has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Mylynda Massart
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
2 shared publications - Brianna M. Brooks
School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
1 shared publication - Carolyn Maxwell
Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
1 shared publication Christine Munro
Department of Family Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
1 shared publication- Christine Munro
University of Pittsburgh
1 shared publication - Erika N. Dreikorn
University of Pittsburgh, Clinical Translational Science Institute
1 shared publication
Latest Publications
- Open Access
- 8 November 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (11) , 543
Utilizing Pharmacogenetic Results to Optimize Medication Management in Hospice Care: A Pilot Study
Background: Pharmacogenetics (PGx), which examines how genetic variations influence drug metabolism and response, offers promise in hospice care where patients commonly experience polypharmacy, complex symptoms, and limited life expectancy. This study assessed the utility of PGx results in guiding medication adjustments to improve symptom management at the end of life. Methods: A retrospective chart review was conducted on ten patients enrolled in a Precision Hospice Program who had PGx results for six key metabolic genes. A PGx-trained pharmacist reviewed Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline-based recommendations, which were discussed during interdisciplinary hospice team meetings. Results: Patients had a mean age of 85.7 years and were prescribed an average of 17.9 medications. Among the 27 prescriptions reviewed, actionable gene–drug interactions were identified, primarily involving antidepressants and analgesics. Three patients underwent medication changes based on PGx guidance, including switching from citalopram to bupropion and adding morphine to tramadol therapy, which improved symptom control. Conclusion: While not yet routinely implemented in hospice settings, this pilot study suggests PGx-guided prescribing can support personalized medication decisions and enhance emotional and physical comfort in end-of-life care when test results are available.
- 8 November 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (11) , 543
Open AccessUtilizing Pharmacogenetic Results to Optimize Medication Management in Hospice Care: A Pilot Study
Background: Pharmacogenetics (PGx), which examines how genetic variations influence drug metabolism and response, offers promise in hospice care where patients commonly experience polypharmacy, complex symptoms, and limited life expectancy. This study assessed the utility of PGx results in guiding medication adjustments to improve symptom management at the end of life. Methods: A retrospective chart review was conducted on ten patients enrolled in a Precision Hospice Program who had PGx results for six key metabolic genes. A PGx-trained pharmacist reviewed Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline-based recommendations, which were discussed during interdisciplinary hospice team meetings. Results: Patients had a mean age of 85.7 years and were prescribed an average of 17.9 medications. Among the 27 prescriptions reviewed, actionable gene–drug interactions were identified, primarily involving antidepressants and analgesics. Three patients underwent medication changes based on PGx guidance, including switching from citalopram to bupropion and adding morphine to tramadol therapy, which improved symptom control. Conclusion: While not yet routinely implemented in hospice settings, this pilot study suggests PGx-guided prescribing can support personalized medication decisions and enhance emotional and physical comfort in end-of-life care when test results are available.
- Open Access
- 1 June 2025
- Vol. 34 (3) , e70051
The case for integrating genetic counselors into primary care: A paradigm shift for our profession.
The integration of genetic counselors (GCs) into primary care represents an opportunity for a transformative shift in healthcare delivery, bridging the gap between the historical medical genetics delivery model and the increasing need for genetic services. This paradigm aligns the holistic ethos of primary care with the specialized expertise of genetic counseling and frontline access to preventive care, addressing critical barriers in genetic services. Current genetic service delivery models, concentrated in tertiary care settings, face limitations, including access disparities, fragmented care, and inefficiencies that disproportionately affect underserved populations. Embedding GCs within primary care leverages GCs' unique skills to enhance personalized healthcare delivery, improve risk assessment, and facilitate the implementation of precision medicine. GCs in primary care can streamline referrals, manage routine genetic concerns, and provide genetic continuity of care across the patient's lifespan. This integration ensures that genetic insights are contextualized within patients' day-to-day healthcare, fostering equitable and efficient access to genomic medicine. We explore the potential impact of primary care genetic counselors (PCGCs) on healthcare systems, emphasizing the alignment of their scope of practice with primary care principles such as accessibility, comprehensiveness, and continuity. By addressing evolving patient needs and collaborating with primary care teams, PCGCs can increase patient access, reduce system inefficiencies, alleviate pressures on specialty genetics services, and improve health equity. This paper advocates for a collaborative model where GCs are embedded within primary care, enabling proactive, prevention-focused interventions and enhancing patient outcomes. By integrating genetics into primary care settings, we reimagine genetic healthcare delivery to maximize the benefits of genomic medicine for all individuals. This paradigm shift underscores the urgency of addressing systemic barriers and advancing the role of GCs in healthcare to improve patient and clinician experiences, better population health, and achieve greater health equity.
- 1 June 2025
- Vol. 34 (3) , e70051
Open AccessThe case for integrating genetic counselors into primary care: A paradigm shift for our profession.
The integration of genetic counselors (GCs) into primary care represents an opportunity for a transformative shift in healthcare delivery, bridging the gap between the historical medical genetics delivery model and the increasing need for genetic services. This paradigm aligns the holistic ethos of primary care with the specialized expertise of genetic counseling and frontline access to preventive care, addressing critical barriers in genetic services. Current genetic service delivery models, concentrated in tertiary care settings, face limitations, including access disparities, fragmented care, and inefficiencies that disproportionately affect underserved populations. Embedding GCs within primary care leverages GCs' unique skills to enhance personalized healthcare delivery, improve risk assessment, and facilitate the implementation of precision medicine. GCs in primary care can streamline referrals, manage routine genetic concerns, and provide genetic continuity of care across the patient's lifespan. This integration ensures that genetic insights are contextualized within patients' day-to-day healthcare, fostering equitable and efficient access to genomic medicine. We explore the potential impact of primary care genetic counselors (PCGCs) on healthcare systems, emphasizing the alignment of their scope of practice with primary care principles such as accessibility, comprehensiveness, and continuity. By addressing evolving patient needs and collaborating with primary care teams, PCGCs can increase patient access, reduce system inefficiencies, alleviate pressures on specialty genetics services, and improve health equity. This paper advocates for a collaborative model where GCs are embedded within primary care, enabling proactive, prevention-focused interventions and enhancing patient outcomes. By integrating genetics into primary care settings, we reimagine genetic healthcare delivery to maximize the benefits of genomic medicine for all individuals. This paradigm shift underscores the urgency of addressing systemic barriers and advancing the role of GCs in healthcare to improve patient and clinician experiences, better population health, and achieve greater health equity.